Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine: a retrospective real-world study in China
10.1080/14760584.2023.2239911
Saved in:
Main Authors: | Ruogu Meng, Rui Ma, Jianmei Wang, Peipei Liu, Zuoxiang Liu, Bingjie He, Zhike Liu, Yu Yang, Siyan Zhan |
---|---|
Other Authors: | OBSTETRICS & GYNAECOLOGY |
Format: | Article |
Published: |
Taylor & Francis
2024
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/246758 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants from Asian Countries
by: S. M. Garland, et al.
Published: (2019) -
Immunogenicity and safety of a 9-valent HPV vaccine
by: Pierre Van Damme, et al.
Published: (2018) -
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
by: Sven Eric Olsson, et al.
Published: (2020) -
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
by: Russell, F.M., et al.
Published: (2014) -
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
by: Wilck M.
Published: (2023)